The Blame Lands on the Wrong Desk
Premiums go up. Employees get angry. And HR absorbs the hit. That's the cycle, and it's getting worse. SHRM and the International Foundation of Employee Benefit Plans project a 10% healthcare cost increase for 2026, up from 8% the year before. HR professionals didn't cause that. But they're the ones explaining it.
The real drivers aren't inside your building. Catastrophic claims, specialty drugs, and GLP-1 medications are doing the heavy lifting on cost growth, according to that same IFEBP data. No benefits team controls any of that.
Yet the accountability somehow lands on the team managing open enrollment. That accountability gap is a retention problem. When HR directors spend renewal season defending decisions made by actuaries and carrier networks, something is broken. Not in the benefits. In how the whole thing is structured and communicated.
Plan Design Changes Help. Inaction Has a Price Tag.
Here's a number worth knowing. Brown and Brown's 2026 healthcare cost outlook found that without any plan design changes, employers would have faced a 12% increase. Active interventions brought that down to 10%. That two-point gap is not small.
On a $2 million premium spend, that's $40,000. On $10 million, it's $200,000. Bring that data to your CFO before renewal, not during it. The conversation shifts from "here's what things cost" to "here's what we did to reduce it."
But plan design changes aren't free either. They have winners and losers. Moving employees from a group plan to a stipend arrangement sounds clean on a spreadsheet. Some employees come out ahead. Others, especially those with dependents or chronic conditions, can lose real ground.
Transitions need analysis and communication, not just cost math. Skipping that step is how HR ends up back at square one with angry emails from different employees.
Prescription Drug Costs Are a Flashpoint You Can't Ignore
GLP-1s alone are reshaping the actuarial assumptions behind most mid-market plans. But the drug cost problem runs deeper than any single drug class. PBM rebate pass-through language is murkier than it looks, even in contracts that say "100% pass-through."
GPO arrangements sit upstream of the PBM. Rebates get netted before they ever reach the pass-through calculation. The Lark Health summary of 2026 plan sponsor challenges describes this as one of the most complicated cost environments plan sponsors have faced yet.